Pfizer's 25-Valent Pediatric Pneumococcal Conjugate Vaccine Candidate Shows Robust Phase 2 Data at IDWeek 2026
Pfizer presented Phase 2 data at IDWeek 2026 showing its 25-valent pediatric pneumococcal vaccine candidate (25vPnC) elicited robust immune responses against all 25 serotypes in infants, with safety comparable to PREVNAR 20. The candidate showed an enhanced response against the historically challenging serotype 3 — GMCs 8.8-fold higher than PREVNAR 20 after Dose 3 and roughly 15-fold higher after Dose 4 — and covered five new serotypes that account for an additional ~30% of pediatric invasive pneumococcal disease in the U.S.
Key figures
- Drug Name
- PF-07872412 (25vPnC)
- Phase Of Trial
- Phase 2
- Phase3 participants
- up to 6,830
- Serotype3 share of pediatric ipd
- 10.6%
- Serotype3 gmc fold increase dose3
- 8.8
- Serotype3 gmc fold increase dose4
- approximately 15-fold
- New serotypes additional ipd coverage
- ~30%
- Serotypes covered share of pediatric ipd
- approximately 84%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.